Back to Hematology
Hematologyv2022Evidence-Based

International Consensus Classification (ICC) Diagnostic Criteria for Systemic Mastocytosis

Diagnoses systemic mastocytosis according to the International Consensus Classification (ICC) criteria using morphological, immunophenotypic, and molecular parameters. The ICC criteria refine the WHO classification system with enhanced diagnostic specificity for mast cell disorders.

Clinical Input Parameters

Clinical Assessment
Awaiting Parameters
diagnostic result
—Points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The International Consensus Classification (ICC) Diagnostic Criteria for Systemic Mastocytosis is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Systemic Mastocytosis diagnosed if: Major Criterion present OR ≥3 Minor Criteria present

Clinical Pearls & Practice Notes

  • High-sensitivity PCR recommended for KIT mutation detection with variant allele frequency (VAF) ≥1%
  • Exclude other potential genetic variants and secondary causes of elevated tryptase
  • Consult additional pathology expertise if initial morphological results are inconclusive
  • The elevated tryptase criterion is not applicable in SM with associated myeloid neoplasm (SM-AMN)
  • Multifocal mast cell infiltrates must contain ≥15 mast cells in aggregates to meet major criterion
  • Atypical morphology includes spindle-shaped cells and immature mast cell features

Evidence & Literature Citations

  1. Leguit RJ, van der Linden MP, Jansen JH, Hebeda KM, Lam KH, Leenders WP, et al. The international consensus classification of mastocytosis and related entities. Virchows Arch. 2023 Jan;482(1):99-112. doi: 10.1007/s00428-022-03454-6.
  2. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 Sep 15;140(11):1200-1228. doi: 10.1182/blood.2022015850.
  3. Valent P, Akin C, Bonadonna P, Hartmann K, Alvarez-Twose I, Brockow K, et al. Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. HemaSphere. 2021 Oct 29;5(11):e646. doi: 10.1097/HS9.0000000000000646.

Score Interpretation Ranges

Tier 1≤ pts

ICC criteria met

Tier 2≤ pts

ICC criteria not met

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.